***TASK*** the task is to summarize an input biomedical literature in six sentences 
    ***INPUT*** the input is a biomedical literature 
    ***OUTPUT*** the output is the summary of an input biomedical literature in six sentences 
    ***DOCUMENTATION*** 
    ***EXAMPLES*** 
    Input: Background : Single small enhancing CT lesions ( SSECTL ) of the brain with or without perifocal oedema are common in patients with symptomatic epilepsy in India . Solitary cysticercus granuloma , a benign form of parenchymal neurocysticercosis , is considered to be the most common aetiology for SSECTL . Definite information is lacking regarding the effectiveness of antiparasitic treatment on resolution of these lesions and on long term seizure recurrence . Objective : To evaluate the response to albendazole treatment in patients who had SSECTL and new onset seizures treated with antiepileptic drugs ( AED ) in a prospect i ve clinical trial . Methods : 43 patients who presented with new onset seizures and were documented to have SSECTL were alternatively allocated to receive albendazole 15 mg/kg/day for 2 weeks or no cysticidal therapy . All patients were treated with AED and followed for at least 6 months for seizure recurrence , and serial CT scans were obtained at 4 weeks , 3 months and at study completion . Results : 28 ( 65 % ) patients were aged 5–25 years and 31 ( 72 % ) presented clinical ly with partial motor seizures with or without generalisation . Most of the SSECTL were ring lesions ( 75 % ) and located in and around the sensory – motor cortex at the gray – white junction ( 65 % ) . In the albendazole group , 56 % of patients compared with 35 % in the control group showed resolution of SSECTL ( p = 0.154 ) at 1 month . 22 of 23 patients ( 95.6 % ) , who received albendazole , compared with 14 of 20 patients ( 70 % ) in the control group , demonstrated radiological resolution on study completion ( p = 0.03 ) . Punctate residual calcification and seizure recurrence were observed in four patients ( 9.3 % ) in the control group and in three ( 7 % ) patients in the albendazole group ( p = 0.47 ) . Conclusions : In patients presenting with seizures due to single viable parenchymal neurocysticercosis , albendazole hastens the resolution of SSECTL if treatment is given in the early phase of the illness Background : A combination of albendazole and praziquantel was more effective than albendazole alone in destroying Taenia cysts  in an animal model . There are no such studies in humans . Objective : To evaluate the efficacy and safety of a combination of albendazole and praziquantel in children with seizures and single small enhancing computerized tomographic lesions . Study Type : Prospect i ve , interventional , r and omized , placebo-controlled , double blind clinical trial at a tertiary hospital in North India . Subjects : One hundred twelve children with seizures for <3 months and single lesion neurocysticercosis ; 9 lost to follow-up . Intervention : All children received albendazole ( 15 mg/kg/d ) for 7 days with either praziquantel or placebo ( 75 mg/kg/d ) for 1 day according to r and om allocation . Repeat CT scans were done after 1 , 3 , and 6 months . All children were followed up for at least 6 months . Results : Fifty-three children received praziquantel ( group A ) and 50 placebo ( group B ) . Complete resolution of lesions was seen in 60 % and 72 % of children at 3 and 6 months in group A versus 42 % and 52 % of children in group B. Nonresolution and calcification were higher in group B than in group A at 3 months ( B : 28 % , 14 % ; A : 12 % , 8 % ) and 6 months ( B : 16 % , 22 % ; A : 6 % , 9 % ) , but the differences were not statistically significant . Seizure control and side effects were similar in the 2 groups . Conclusions : A combination therapy for albendazole and praziquantel was statistically comparable to sole therapy with albendazole in eradicating lesions and preventing seizures Single small enhancing computed tomographic ( CT ) lesions representing cysticercus granuloma are a common cause of focal seizures in children . Controversy exists regarding the efficacy of various modalities of treatment . We conducted a r and omized prospect i ve trial to evaluate the efficacy of corticosteroids , albendazole , and corticosteroids with albendazole in children with focal seizures and single small enhancing CT lesions . The study population consisted of 133 children with focal seizures of recent onset ( < 3 months ) and single small enhancing CT lesions who presented to the Neurocysticercosis Clinic of Pediatric Neurology Services at the Advanced Pediatrics Centre , Postgraduate Institute of Medical Education and Research , an urban teaching and tertiary care hospital in Ch and igarh , North India . All children were r and omly assigned to receive corticosteroids ( group S ) , albendazole ( group A ) , or both corticosteroids and albendazole ( group SA ) for 28 days . CT was done at 3 and 6 months after enrollment in the study . Of the 133 patients enrolled , 23 were lost to follow-up . Of the remaining 110 patients , 38 patients were in group S , 37 in group A , and 35 in group SA . All children were followed up for at least 18 months . Disappearance of the lesion on CT scan was noted in 52.6 % of patients in group S , 59.5 % in group A , and 62.9 % in Group SA ( P > .1 ) at the 3-month follow-up . After the 6-month follow-up , disappearance of the lesion was noted in 76.3 % in group S , 75.7 % in group A , and 74.2 % in group SA ( P > .1 ) . Twenty-three patients had seizure recurrence while on antiepilepsy drugs : 36.8 % of patients in group S , 13.5 % in group A , and 11.4 % in group SA ( P < .05 ) . Seizure recurrence after antiepilepsy drug withdrawal was seen in seven children ( three in group S and two each in groups A and SA ) . In conclusion , there was no significant difference in resolution of CT lesions in the three therapy groups at 3 and 6 months of follow-up . Children in the corticosteroid group had significantly more seizure recurrences while on antiepilepsy drugs . ( J Child Neurol 2004;19:323 - 327 ) Praziquantel and albendazole have been recently described as effective drugs for treatment of intraparenchymal brain cysticercosis .  We performed a prospect i ve study comparing the efficacy of these drugs . Twenty-two patients were treated with praziquantel and 21 with albendazole . In addition , 16 patients were treated with symptomatic drugs only and used as controls . Treatment was discontinued in two patients receiving praziquantel and one patient receiving albendazole owing to acute decompensation of the increased intracranial pressure , and one of them died . Albendazole and praziquantel were effective when compared with the control group . However , albendazole was significantly more effective than praziquantel in reducing the total number of cysts in the computed tomographic scans ( 88 % vs 50 % ) . Despite these results , however , analysis of clinical course showed a high frequency of neurologic sequelae . Considering the risks and fallibility of anticysticercal therapy , the real solution for this serious disease continues to be prophylaxis of infestation Single small enhancing computerized tomographic ( CT ) lesions ( SSECTLs ) are common in children with focal seizures . However , there is a paucity of systematic information regarding their morphometry , effect of albendazole therapy and long-term outcome . The objectives were to study the pattern of SSECTL on radiological follow up , alterations made by albendazole therapy , and correlation with seizure recurrence . A r and omized , placebo controlled , double blind trial was carried out at the Advanced Pediatric Center , PGIMER , an urban tertiary-care teaching hospital . Sixty-three children between 2 and 12 years of age with focal seizures for < 3 months and SSECTLs were included in the study . All children were r and omly assigned to receive either albendazole ( 15 mg/kg/day ) or placebo for 28 days . CT scan was done at 1 and 3 months after beginning treatment . Codes opened after 6 months of recruitment in the study showed that 31 had received albendazole and 32 had received placebo . Over a period of 3 months , natural resolution of SSECTL passed through many stages . Albendazole was seen to accelerate this natural process as evident by the progression of various morphometric markers . An increase in the size of the lesion was associated with early seizure recurrence Thirty-six patients with subarachnoid and intraventricular cysticercosis were r and omly assigned to receive albendazole at 15 or 30 mg/kg/day plus dexamethasone for 8 days . Results favored a higher dose , with larger cyst reduction on MRI at 90 and 180 days and higher albendazole sulfoxide levels in plasma . An albendazole course at 30 mg/kg/day combined with corticosteroids is safe and more effective than the usual dose . A single treatment was insufficient in intraventricular and giant cysts Twenty-six patients with single enhancing brain lesion ( SEL ) were openly assigned to receive single-day praziquantel therapy ( n=14 ) , or not ( n=12 ) . From 14 treated patients , complete resolution was found in 11 , partial resolution in two , and the remaining case was later diagnosed as an arteriovenous malformation . Side effects presented in only one patient and remitted in the same day with symptomatic treatment . Conversely , the lesions persisted unchanged in six of 12 patients in the non-treatment group . Untreated patients with persisting lesions were prescribed praziquantel treatment . After this , SELs disappeared in three cases , other diagnoses ( brain tuberculoma and arteriovenous malformation ) were made in two , and one was not evaluated . When analyzed in regard to the baseline serology , resolution of lesions on computed tomography was found in 13 ( complete=12 , partial=1 ) of 14 seropositive patients , whereas it only happened in six ( complete=5 , partial=1 ) of 12 seronegative patients . Serological screening defines a subset of SEL patients with good prognosis . If antiparasitic therapy is to be used in patients with SEL , and we can not find a strong argument against it , single-day praziquantel is the regimen of choice based on duration , costs , and minimal side effects BACKGROUND Neurocysticercosis is the main cause of adult-onset seizures in the developing world . Whether therapy with antiparasitic agents results in improved seizure control has been question ed because of the lack of adequate , controlled studies . METHODS We conducted a double-blind , placebo-controlled trial in which 120 patients who had living cysticerci in the brain and seizures treated with antiepileptic drugs  were r and omly assigned to receive either 800 mg of albendazole per day and 6 mg of dexamethasone per day for 10 days ( 60 patients ) or two placebos ( 60 patients ) . The patients were followed for 30 months or until they had been seizure-free for 6 months after the doses of the antiepileptic drugs had been tapered . The efficacy of treatment was measured as the decrease in the number of seizures after treatment . RESULTS In the albendazole group , there was a 46 percent reduction in the number of seizures ( 95 percent confidence interval , -74 to 83 percent ) during months 2 to 30 after treatment . This reduction , which was not statistically significant , was composed of a nonsignificant reduction of 41 percent in the number of partial seizures ( 95 percent confidence interval , -124 to 84 percent ) and a significant 67 percent reduction in the number of seizures with generalization ( 95 percent confidence interval , 20 to 86 percent ) . Most of the difference in the number of partial seizures was attributable to a few patients who had many seizures during follow-up . The proportions of patients who had partial seizures during follow-up were similar in the two groups ( 19 of 57 in the albendazole group and 16 of 59 in the placebo group ) , but the patients in the placebo group had a greater tendency to have seizures with generalization ( 22 of 59 , vs. 13 of 57 in the albendazole group ; risk ratio , 1.63 ; 95 percent confidence interval , 0.91 to 2.92 ) . More of the intracranial cystic lesions resolved in the albendazole group than in the placebo group . With the sole exception of abdominal pain , side effects did not differ significantly between the two groups . CONCLUSIONS In patients with seizures due to viable parenchymal cysts , antiparasitic therapy decreases the burden of parasites and is safe and effective , at least in reducing the number of seizures with generalization BACKGROUND Single small enhancing computerized tomographic ( CT ) lesions ( SSECTLs ) are common in children with focal seizures . These are considered to represent solitary cysticercus granulomas . Controversy exists regarding their treatment . OBJECTIVE To evaluate the efficacy of albendazole in cases of focal seizures with SSECTLs . DESIGN R and omized , placebo-control 
    Output:
    
In patients with viable lesions , evidence from trials of adults suggests albendazole may reduce the number of lesions .
In trials of non-viable lesions , seizure recurrence was substantially lower with albendazole , which is counter-intuitive .